Conference
The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: A double-blind, placebo-controlled trial in patients with ESRD
Abstract
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)-mediated lowering of serum cholesterol has been associated with a significant reduction in cardiovascular morbidity and mortality. Recent studies suggest that additional non-lipid lowering effects (eg, endothelial stabilization, anti-inflammatory, antithrombogenic) may be important in modulating their effectiveness. Dyslipidemia is common in end-stage renal disease (ESRD), …
Authors
Keane WF; Brenner BM; Mazzu A; Agro A; Committee FTCS
Volume
37
Pagination
pp. s48-s53
Publisher
Elsevier
Publication Date
January 2001
DOI
10.1053/ajkd.2001.20739
Conference proceedings
American Journal of Kidney Diseases
Issue
1
ISSN
0272-6386